Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Realty, healthcare stocks lead the losses
Wed, 17 Dec Closing

The Indian markets slipped back into the red towards the end of the trading session after recovering early losses in the post-noon trading session. The BSE-Sensex closed lower by about 71 points or 0.3%, while the NSE-Nifty closed lower by about 38 points. Barring banking, metal and oil & gaseous stocks, weakness was seen across the board, with realty and healthcare stocks leading the pack of losers. Mid and smallcaps ended the day on a weak note with their respective indices down by about 0.6% and 1.1% respectively.

Stock markets in other parts of Asia ended the day on a mixed note, while sentiments in Europe seemed negative at the time of writing. The rupee had fallen to Rs 63.56 to the dollar at the time of writing.

Mining stocks have closed mainly in the red with Ashapura Minechem and MOIL Ltd leading the losses. As per the provisional data from online market operator mjunction's data (based on the monitoring of vessel positions and figures from shipping firm), coal imports have risen 7 % to a three-month high of 16.08 million tonnes (MT) in November on a year on year basis. One of the reasons for increase in imports could be falling coal prices prompting companies to stock up on the commodity. However, as rupee continues to fall on account of brewing concerns in Russia, coal imports may become expensive. It is noteworthy that India buys most of its coal from Indonesia, Australia and South Africa .

Stocks of Indian pharmaceutical companies ended the day mainly in the red with Wockhardt and Aurobindo Pharma leading the pack of losers. As per a leading financial daily, the drug maker Novartis has moved to Delhi High Court seeking to restrain Cipla Ltd from selling an affordable version of its respiratory drug Onbrez in India. Novartis aims to shut down an affordable drug by Cipla and has clearly said that it will not locally manufacture, but only import the drug in question. As per the industry experts, Novartis' stand is a clear violation of IP laws, that suggest that the patent has to be 'locally worked' - i.e, be affordable and available to patients in the country. A final verdict on the case is expected in January 2015.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Realty, healthcare stocks lead the losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.